Male hormonal contraception: Suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men

Journal of Andrology

Volumn 25, Issue 5, 2004, Pages 720-727

  Gui, You Lun ^a   He, Chang Hai ^a   Amory, John K ^b   Bremner, William J ^b   Zheng, E Xiang ^a   Yang, Jie ^a   Yang, Pei Juan ^a   Gao, Er Sheng ^a  

^a SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgens; Contraceptive; Family planning; Progestins

Indexed keywords

ANDROGEN; GESTAGEN; LEVONORGESTREL; MALE CONTRACEPTIVE AGENT; TESTOSTERONE UNDECANOATE;

ADULT; ARTICLE; AZOOSPERMIA; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG IMPLANT; DRUG MEGADOSE; FAMILY PLANNING; HORMONAL CONTRACEPTION; HUMAN; MALE; NORMAL HUMAN; OLIGOSPERMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SIDE EFFECT; SPERMATOGENESIS; SPERMATOZOON COUNT;

EID: 4143131163     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1939-4640.2004.tb02846.x     Document Type: Article

References (29)

1. Alvarez F, Brache V, Tejada AS, Cochon L, Faundes A. Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants. Contraception. 1998;58:211-214.
2. Anawalt BD, Amory JK. Advances in male hormonal contraception. Ann Med. 2001;33:587-595.
3. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower-dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher-dosage combination. J Androl. 1999;20: 407-414.
4. Anawalt BD, Herbst KL, Matsumoto AM, Mulders TM, Coelingh-Bennink HJ, Bremner WJ. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high density lipoprotein suppression. Fertil Steril. 2000;74:707-714.
5. Anderson RA, Baird DT. Male contraception. Endocr Rev. 2002;23:735-762.
6. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996;81:757-762.
7. Edwards A, Hammond HS, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992;12:241-253.
8. Gao E, Lin C, Gui Y, Li Lamei, He C. Inhibiting effects of Sino-implant plus testosterone undecanoate (TU) on spermatogenesis in Chinese men. Reprod Contraception. 1999;10:98-105.
9. Gonzalo ITG, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002;87:3562-3572.
10. Gu YQ, Wang XH, Xu D, Peng L, Cheng L-F, Huang M-K, Huang Z-J, Zhang G-Y. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in health Chinese men. J Clin Endocrinol Metab. 2003;88:562-568.
11. Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab. 1996;81:4113-4121.
12. He C, Lin C, Bremner WJ, Gui Y, Li L, Gao E. Effects of Sino-implant with testosterone undecanoate (TU) on the pituitary-gonadal axis in Chinese men. Reprod Contraception. 2001;21:86-91.
13. Johnson L, Barnard JJ, Rodriguez L, Smith EC, Swerdloff RS, Wang XH, Wang C. Ethnic differences in testicular structure and spermatogenic potential may predispose testes of Asian men to a heightened sensitivity to steroidal contraceptives. J Androl. 1998;19:348-357.
14. Kamischke A, Ploger D, Venherm S, Von Eckardstein S, Von Eckardstein A, Nieschlag E. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol. 2000;53:43-52.
15. Kamischke A, Venherm S, Ploger D, Von Eckarstein S, Nieschlag E. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab. 2001;86:303-309.
16. Kinninburgh D, Anderson RA, Baird DT. Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. J Androl. 2001;22:88-95.
17. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313-340.
18. Martin CW, Anderson RA, Cheng L, et al. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod. 2000;15:637-645.
19. Meriggiola MC, Bremner WJ, Costantino A, Di Cintio G, Flamigni C. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum Reprod. 1998;13:1225-1229.
20. Meriggiola MC, Bremner WJ, Paulsen CA, et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab. 1996; 81:3018-3023.
21. Narula A, Gu YQ, O'Donnell L, Stanton PG, Robertson DM, McLachlan RI, Bremner WJ. Variability in sperm suppression during testosterone administration to adult monkeys is related to follicle stimulating hormone suppression and not to intratesticular androgens. J Clin Endocrinol Metab. 2002;87:3399-3406.
22. von Eckardstein S, Schmidt A, Kamischke A, Simoni M, Gromoll J, Nieschlag E. CAG repeat length in the androgen receptor gene and gonadotropin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol. 2002;57:647-655.
23. Wang C, Berman NG, DerVelduis JDT, McDonald V, Steiner B, Swerdloff RS. Graded testosterone infusions distinguish gonadotropin negative-feedback responsiveness in Asian and white men. J Clin Endocrinol Metab. 1998;83:870-876.
24. World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 3rd ed. Cambridge, United Kingdom: Cambridge University Press; 1992.
25. World Health Organization Task Force in Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336:955-959.
26. World Health Organization Task Force in Methods for the Regulation of Male Fertility. contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65: 821-829.
27. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003;24:183-217.
28. Yu B, Handelsman DJ. Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia. J Clin Endocrinol Metab. 2001;86:4406-4411.
29. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab. 1999;84:3642-3647.